Allround Doctors Secures 7 Billion KRW Series A Funding

Development of Digital Medical Devices for Cancer Patients
Partnerships with Global Pharmaceutical Companies and Samsung Electronics

Digital healthcare startup Allround Doctors announced on the 6th that it has secured 7 billion KRW in Series A funding. This round was led by existing investor Aeon Investment, with participation from UTC Investment, Futureplay, Korea Investment Partners, and KB Investment.

Allround Doctors is a digital healthcare startup developing digital medical devices for cancer patients. It plans to conduct clinical trials within the year for ‘CANMORE,’ a solution designed to improve chemotherapy adherence and enhance the quality of life for breast cancer patients undergoing chemotherapy.

Based on CANMORE, Allround Doctors developed ‘CANMORE PRO,’ clinical trial software for monitoring chemotherapy side effects, and has launched its commercial service. In May, it received approval from global pharmaceutical companies Daiichi Sankyo and AstraZeneca to provide services to over 10 university hospitals, including Yonsei Cancer Hospital, for clinical trials of the blockbuster immuno-oncology drug Enhertu.

Additionally, the technology linking cancer patients’ chemotherapy side effect symptoms with wearable device data was developed using the open-source project ‘Samsung Health Stack,’ led by Samsung Electronics. This was showcased as a case study at the annual Samsung Developer Conference held in the United States.

With this investment, Allround Doctors plans to focus on enhancing the medical safety and technological advancement of CANMORE and prepare for full-scale entry into the Japanese market. Lee Jong-hyun, CEO of Aeon Investment, said, “Allround Doctors is a rapidly growing team formed by collaboration between internal medicine specialists and IT developers. Along with developing digital medical devices to improve medication adherence for breast cancer patients, we also look forward to the clinical effects of the ‘cancer survivor-centered personalized healthcare technology,’ which is currently under research and exploratory clinical trials with the National Cancer Center and regional cancer centers.”

Kwack Sung-dong, CEO of Allround Doctors, stated, “Currently, in South Korea, the management of chemotherapy side effects for cancer patients is not supported by medical fees, causing inconvenience for both patients and doctors. In Europe, patient self-reporting is increasingly standardized as a guideline by the largest oncology societies, and self-monitoring and management are becoming standard practices with active discussions on medical fees. With this investment, we aim to achieve the medical safety and technological advancement goals of CANMORE in collaboration with domestic oncology medical staff.”